Marith van Schrojenstein Lantman, Anne-Els van de Logt, Elma Prudon-Rosmulder, Marloes Langelaan, Ayşe Y Demir, Steef Kurstjens, Armando van der Horst, Aldy Kuypers, Aram Greuter, Jenny Kootstra-Ros, Eline van der Hagen, Marlies Oostendorp, Roseri de Beer, Christian Ramakers, Dirk Bakkeren, Fokke Lindeboom, Dennis van de Wijngaart, Marc Thelen, Jack Wetzels, Miranda van Berkel
OBJECTIVES: Measurement of plasma albumin is pivotal for clinical decision-making in patients with chronic kidney disease (CKD). Routinely used methods as bromocresol green (BCG) and bromocresol purple (BCP) can suffer from aselectivity, but the impact of aselectivity on the accuracy of plasma albumin results of CKD-patients is still unknown. Therefore, we evaluated the performance of BCG-, BCP- and JCTLM-endorsed immunological methods in patients with various stages of CKD. METHODS: We evaluated the performance of commonly used albumin methods in patients with CKD stages G1 through G5, the latter divided in two groups based on whether they received hemodialysis treatment...
July 4, 2023: Clinical Chemistry and Laboratory Medicine: CCLM